Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021015132
Abstract: Ibrutinib and acalabrutinib are Bruton's tyrosine kinase inhibitors (BTKis) that are effective therapies for chronic lymphocytic leukemia (CLL). While clonal evolution during ibrutinib treatment has been investigated, the impact of clonal evolution during acalabrutinib treatment… read more here.
Keywords: clonal evolution; evolution; treatment; ibrutinib acalabrutinib ... See more keywords
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2018.193391
Abstract: Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and phosphorylation of… read more here.
Keywords: aggregation; ibrutinib acalabrutinib; concentrations ibrutinib; btk ... See more keywords
Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12123731
Abstract: Simple Summary The enzyme aldo-keto reductase 1C3 (AKR1C3) is present in several cancers, in which it is capable of actively metabolising different chemotherapy drugs and decreasing their cytotoxic effects. Therefore, the combination with specific inhibitors… read more here.
Keywords: ibrutinib acalabrutinib; inhibitors ibrutinib; cancer cells; cancer ... See more keywords